Shuttle Pharmaceuticals Ownership
| SHPH Stock | USD 0.60 0.00 0.000003% |
Shuttle |
Shuttle Stock Ownership Analysis
About 19.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 4.25. Shuttle Pharmaceuticals had not issued any dividends in recent years. The entity had 1:8 split on the 13th of August 2024. Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. The company was founded in 2012 and is based in Rockville, Maryland. Shuttle Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To find out more about Shuttle Pharmaceuticals contact the company at 240 403 4212 or learn more at https://www.shuttlepharma.com.Besides selling stocks to institutional investors, Shuttle Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Shuttle Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Shuttle Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Shuttle Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
About 19.0% of Shuttle Pharmaceuticals are currently held by insiders. Unlike Shuttle Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Shuttle Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Shuttle Pharmaceuticals' insider trades
Shuttle Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Shuttle Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Shuttle Pharmaceuticals backward and forwards among themselves. Shuttle Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Shuttle Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-12-31 | 306.1 K | Ubs Group Ag | 2024-12-31 | 32.8 K | Geode Capital Management, Llc | 2024-12-31 | 10.9 K | Tower Research Capital Llc | 2024-12-31 | 6.9 K | Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 63.0 | Bank Of America Corp | 2024-12-31 | 23.0 | Hrt Financial Llc | 2024-12-31 | 0.0 |
Shuttle Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Shuttle Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Shuttle Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Shuttle Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dritschilo Anatoly over three months ago Disposition of 8372 shares by Dritschilo Anatoly of Shuttle Pharmaceuticals at 1.605 subject to Rule 16b-3 | ||
Lorber Timothy J. over six months ago Disposition of tradable shares by Lorber Timothy J. of Shuttle Pharmaceuticals subject to Rule 16b-3 | ||
Schafer Joshua over six months ago Disposition of tradable shares by Schafer Joshua of Shuttle Pharmaceuticals subject to Rule 16b-3 | ||
Vander Hoek Michael over six months ago Acquisition by Vander Hoek Michael of 100000 shares of Shuttle Pharmaceuticals subject to Rule 16b-3 | ||
Jacobs Bette over a year ago Sale by Jacobs Bette of 4157 shares of Shuttle Pharmaceuticals | ||
Dritschilo Anatoly over a year ago Bona fide gift to Dritschilo Anatoly of 2100000 shares of Shuttle Pharmaceuticals subject to Section 16 | ||
Brown Milton over a year ago Acquisition by Brown Milton of 25000 shares of Shuttle Pharmaceuticals subject to Rule 16b-3 |
Currently Active Assets on Macroaxis
When determining whether Shuttle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Shuttle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Shuttle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Shuttle Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Shuttle Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.